Massar Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Massar Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.3K	Buy	+17,801	New	+$21.2K	﹤0.01%	265

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Massar Capital Management's AKBA Position: Q2 2026 in Review

Massar Capital Management opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 17,801 shares worth $20.3K. The stake represents ﹤0.01% of the portfolio and ranks #265 among its holdings.

170 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Massar Capital Management held 17,801 shares of Akebia Therapeutics worth $20.3K as of Q2 2026.
Akebia Therapeutics was a new Massar Capital Management position in Q2 2026.
Akebia Therapeutics made up ﹤0.01% of Massar Capital Management's portfolio in Q2 2026, its #265 holding.
170 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Massar Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.